We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

29 hedge funds and large institutions have $103K invested in Alaunos Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.09% less ownership

Funds ownership: 4.51%4.42% (-0.09%)

3% less funds holding

Funds holding: 3029 (-1)

25% less capital invested

Capital invested by funds: $137K → $103K (-$33.6K)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
29
Holders Change
-1
Holders Change %
-3.33%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
3
Reduced
6
Closed
4
Calls
Puts
Net Calls
Net Calls Change

TCRT Hedge Fund Activity: Q1 2025 in Review

29 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2025, worth a combined $103K — down 25% from $137K a quarter earlier.

Fund positioning in TCRT was balanced in Q1 2025: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 6 trimmed.

The largest buyer was Tower Research Capital (TRC), adding an estimated $863. The largest seller was Citigroup, exiting entirely with an estimated $3.03K sold.

  • 29 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2025, down from 30 in Q4 2024.
  • Funds reported $103K of Alaunos Therapeutics stock for Q1 2025, down 25% quarter-over-quarter.
  • 4 funds opened new Alaunos Therapeutics positions in Q1 2025 and 4 closed out, a net change of 0 holders.
  • The largest Alaunos Therapeutics buyer in Q1 2025 was Tower Research Capital (TRC), an estimated $863 added.
  • The largest Alaunos Therapeutics seller in Q1 2025 was Citigroup, an estimated $3.03K sold.

Based on aggregated 13F filings for Q1 2025.